Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 The Parenteral Drug ... harmonize global post-approval changes protocols. The ... the topic expressed by industry participants and regulatory authority ... this month in Washington, DC . ... on hand for the workshop. Attendees indicated openness to ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... 31, 2011 Reportlinker.com announces that a ... its catalogue: Germany Surgical ... http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment Germany ... Summary GlobalData,s ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an ... the third quarter ended September 30, 2011 and provided ... (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and ... "With the broad postsurgical pain management label granted ...
Cached Medicine Technology:Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 2Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 3Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 4Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 5Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 6Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 7Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 8Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 9
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving ... a meeting took place to discuss the next steps ... the court’s mass tort program. Attorneys for the plaintiffs ... at the Complex Litigation Center in Philadelphia’s City Hall ... The Risperdal lawsuits filed against Johnson & Johnson and ...
(Date:9/19/2014)... September 19, 2014 BearCom, a ... today detailed the key role played by instant, ... in the healthcare industry. , “In healthcare, ... care – and in emergency situations, can save ... life and death,” said Hugh Johnston, Product & ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4
... CT angiography utilizing prospective electrocardiographic (ECG) gating produces ... dose when compared to retrospective ECG gating, according ... Roentgen Ray Society,s annual meeting. , The study ... the University Hospitals Case Medical Center, in Cleveland, ...
... TUESDAY, May 3 (HealthDay News) -- The U.S. Food ... are cracking down on manufacturers of over-the-counter products that ... The agencies jointly sent letters to companies including ... that their products are unproven and violate federal law, ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) -- ... lower their blood sugar level more effectively than just receiving ... review of data. After analyzing the results of ... for longer periods of time was better at bringing blood ...
... to play a key role in tumor survival, a research ... MD Anderson Cancer Center reports in an advance online publication ... suggests that the little-studied protein binds to the tumor-suppressing protein ... it for destruction by proteasomes, which degrade proteins and recycle ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) ... new U.S. study have TVs available for children to watch, ... Academy of Pediatrics, guidelines for television exposure in young kids. ... at daycares may be missing out on the kind of ...
... Cell biologist Daniel Gottschling, Ph.D., a member of the ... been elected to membership in the National Academy of Sciences. ... that can be accorded a U.S. scientist or engineer. "I ... peers," said Gottschling, who will be inducted into the Academy ...
Cached Medicine News:Health News:Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients 2Health News:U.S. Officials Take Aim at Questionable STD Products 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 3Health News:Protein identified as enemy of vital tumor suppressor PTEN 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 3Health News:Cell biologist Daniel Gottschling elected to National Academy of Sciences 2
... immersion objective has a higher numerical aperture ... media helps eliminate surface,reflections and provides an ... excellent objective for fluorescence, brightfield and DIC ... correction collar that allows it to be ...
... is a very versatile light source ... variety of applications anytime a Zeiss ... illumination with optimum protection without heating ... most economical cold-light source that completes ...
... a complete line of ... halogen light sources that ... A solid-state dimmer provides ... our exclusive Modulamp assembly ...
Standard 20x long working distance objectives for greater magnifications of your microtools....
Medicine Products: